Yuksel Burcu, Genc Fatma, Yaman Aylin, Goksu Eylem Ozaydin, Ak Pelin Dogan, Gomceli Yasemin Bicer
Neurology Department, Antalya Training and Research Hospital, Muratpasa, 07050, Antalya, Turkey.
Neurology Department, Fatih Sultan Mehmet Training and Research Hospital, Kadıkoy, 34752, Istanbul, Turkey.
Acta Neurol Belg. 2019 Mar;119(1):55-60. doi: 10.1007/s13760-018-1018-5. Epub 2018 Sep 3.
Hemifacial spasm (HFS) is a chronic disease that is characterized by involuntary tonic and clonic contractions of the muscles innervated by the ipsilateral facial nerve. Botulinum toxin (BTX) is the most effective medical treatment of this condition. The aim of our study was to evaluate stigma among patients diagnosed with HFS and to search quality of life and depression before and after BTX injection. Seven self-rating items (HFS-7) and seven questions related to stigmatization were administered to HFS patients. Participants also answered SF-36 health outcome measure and Beck depression inventory before and 4 weeks after the routine BTX injection. The severity of HFS was graded based on a five-point scale. Descriptive statistics and paired t test were applied. The level of significance was set at α = 0.05. Fourty HFS patients were prospectively included. Twenty-one (%52.5) were female and nineteen were male (47.5%) with a mean age of 57.1 (SD = 12.13; min-max = 27-78). 60% (n: 24) of patients were feeling themselves different from people without HFS. Beck depression inventory scores improved after BTX injection significantly (p < 0.05). All domains of SF-36 showed positive improvement after BTX injections. The improvement in general health perception, physical functioning, and vitality was statistically significant (p < 0.05). Although more than half of the patients felt themselves different from people without HFS, treatment of HFS with BTX significantly improved mental health and physical health, and depressive symptoms of the patients.
面肌痉挛（HFS）是一种慢性疾病，其特征为同侧面神经支配的肌肉出现不自主的强直性和阵挛性收缩。肉毒杆菌毒素（BTX）是治疗这种疾病最有效的药物。我们研究的目的是评估被诊断为HFS的患者的耻辱感，并在BTX注射前后探寻生活质量和抑郁情况。对HFS患者进行了7项自评项目（HFS-7）和7个与耻辱感相关的问题调查。参与者还在常规BTX注射前和注射后4周回答了SF-36健康结果测量量表和贝克抑郁量表。HFS的严重程度采用五分制进行分级。应用描述性统计和配对t检验。显著性水平设定为α = 0.05。前瞻性纳入了40例HFS患者。其中21例（52.5%）为女性，19例（47.5%）为男性，平均年龄为57.1岁（标准差 = 12.13；最小-最大年龄 = 27-78岁）。60%（n = 24）的患者感觉自己与没有HFS的人不同。BTX注射后贝克抑郁量表评分显著改善（p < 0.05）。BTX注射后SF-36的所有领域均显示出积极改善。总体健康感知、身体功能和活力方面的改善具有统计学意义（p < 0.05）。尽管超过一半的患者感觉自己与没有HFS的人不同，但用BTX治疗HFS显著改善了患者的心理健康、身体健康和抑郁症状。
